Mifamurtide: A review of its use in the treatment of osteosarcoma

James E. Frampton, P. M. Anderson, Alexander Ja-Ho Chou, N. C. Federman, S. Ferrari, H. J. Kim, D. M. Loeb, K. Mori

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact®) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection; it is administered by intravenous infusion in conjunction with postoperative multiagent chemotherapy. In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma.In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high-grade, non-metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma.

Original languageEnglish (US)
Pages (from-to)141-153
Number of pages13
JournalPediatric Drugs
Volume12
Issue number3
DOIs
StatePublished - May 27 2010
Externally publishedYes

Fingerprint

Osteosarcoma
Therapeutics
Orphan Drug Production
Chills
Ifosfamide
Ethanolamine
Macrophage Activation
Myalgia
Immunologic Factors
Drug Combinations
Clinical Protocols
mifamurtide
Combination Drug Therapy
Intravenous Infusions
Methotrexate
Pharmaceutical Preparations
Doxorubicin
Nausea
Cisplatin
Headache

Keywords

  • Adis-Drug-Evaluations
  • Osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Frampton, J. E., Anderson, P. M., Chou, A. J-H., Federman, N. C., Ferrari, S., Kim, H. J., ... Mori, K. (2010). Mifamurtide: A review of its use in the treatment of osteosarcoma. Pediatric Drugs, 12(3), 141-153. https://doi.org/10.2165/11204910-000000000-00000

Mifamurtide : A review of its use in the treatment of osteosarcoma. / Frampton, James E.; Anderson, P. M.; Chou, Alexander Ja-Ho; Federman, N. C.; Ferrari, S.; Kim, H. J.; Loeb, D. M.; Mori, K.

In: Pediatric Drugs, Vol. 12, No. 3, 27.05.2010, p. 141-153.

Research output: Contribution to journalReview article

Frampton, JE, Anderson, PM, Chou, AJ-H, Federman, NC, Ferrari, S, Kim, HJ, Loeb, DM & Mori, K 2010, 'Mifamurtide: A review of its use in the treatment of osteosarcoma', Pediatric Drugs, vol. 12, no. 3, pp. 141-153. https://doi.org/10.2165/11204910-000000000-00000
Frampton JE, Anderson PM, Chou AJ-H, Federman NC, Ferrari S, Kim HJ et al. Mifamurtide: A review of its use in the treatment of osteosarcoma. Pediatric Drugs. 2010 May 27;12(3):141-153. https://doi.org/10.2165/11204910-000000000-00000
Frampton, James E. ; Anderson, P. M. ; Chou, Alexander Ja-Ho ; Federman, N. C. ; Ferrari, S. ; Kim, H. J. ; Loeb, D. M. ; Mori, K. / Mifamurtide : A review of its use in the treatment of osteosarcoma. In: Pediatric Drugs. 2010 ; Vol. 12, No. 3. pp. 141-153.
@article{83a636bd795c4f74a4ad356f06735940,
title = "Mifamurtide: A review of its use in the treatment of osteosarcoma",
abstract = "Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact{\circledR}) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection; it is administered by intravenous infusion in conjunction with postoperative multiagent chemotherapy. In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma.In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high-grade, non-metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma.",
keywords = "Adis-Drug-Evaluations, Osteosarcoma",
author = "Frampton, {James E.} and Anderson, {P. M.} and Chou, {Alexander Ja-Ho} and Federman, {N. C.} and S. Ferrari and Kim, {H. J.} and Loeb, {D. M.} and K. Mori",
year = "2010",
month = "5",
day = "27",
doi = "10.2165/11204910-000000000-00000",
language = "English (US)",
volume = "12",
pages = "141--153",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Mifamurtide

T2 - A review of its use in the treatment of osteosarcoma

AU - Frampton, James E.

AU - Anderson, P. M.

AU - Chou, Alexander Ja-Ho

AU - Federman, N. C.

AU - Ferrari, S.

AU - Kim, H. J.

AU - Loeb, D. M.

AU - Mori, K.

PY - 2010/5/27

Y1 - 2010/5/27

N2 - Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact®) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection; it is administered by intravenous infusion in conjunction with postoperative multiagent chemotherapy. In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma.In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high-grade, non-metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma.

AB - Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact®) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection; it is administered by intravenous infusion in conjunction with postoperative multiagent chemotherapy. In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma.In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high-grade, non-metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma.

KW - Adis-Drug-Evaluations

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=77952570963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952570963&partnerID=8YFLogxK

U2 - 10.2165/11204910-000000000-00000

DO - 10.2165/11204910-000000000-00000

M3 - Review article

C2 - 20481644

AN - SCOPUS:77952570963

VL - 12

SP - 141

EP - 153

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 3

ER -